Clarity Pharmaceuticals Ltd (CU6) - Total Liabilities
Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) has total liabilities worth AU$22.86 Million AUD (≈ $16.17 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Clarity Pharmaceuticals Ltd - Total Liabilities Trend (2018–2025)
This chart illustrates how Clarity Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Clarity Pharmaceuticals Ltd to evaluate short-term liquidity relative to the company's equity base.
Clarity Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Clarity Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anhui Landun Photoelectron Co Ltd
SHE:300862
|
China | CN¥380.07 Million |
|
Indointernet Tbk PT
JK:EDGE
|
Indonesia | Rp2.14 Trillion |
|
Beijing SinoHytec Co. Ltd. A
SHG:688339
|
China | CN¥1.61 Billion |
|
MERSEN UNSP.ADR 1/5 EO 2
F:CBE0
|
Germany | €1.01 Billion |
|
Rio2 Ltd
V:RIO
|
Canada | CA$87.09 Million |
|
Zhejiang Sf Oilless Bearing Co Ltd
SHE:300817
|
China | CN¥259.79 Million |
|
Thai Stanley Electric Public Company Limited
BK:STANLY
|
Thailand | ฿2.52 Billion |
|
Zhejiang Runyang New Material Technology Co. Ltd.
SHE:300920
|
China | CN¥424.81 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Clarity Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Clarity Pharmaceuticals Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.50 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Clarity Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Clarity Pharmaceuticals Ltd (2018–2025)
The table below shows the annual total liabilities of Clarity Pharmaceuticals Ltd from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$10.94 Million ≈ $7.74 Million |
+31.32% |
| 2024-06-30 | AU$8.33 Million ≈ $5.90 Million |
+7.91% |
| 2023-06-30 | AU$7.72 Million ≈ $5.46 Million |
+1.78% |
| 2022-06-30 | AU$7.59 Million ≈ $5.37 Million |
+224.81% |
| 2021-06-30 | AU$2.34 Million ≈ $1.65 Million |
+144.26% |
| 2020-06-30 | AU$956.09K ≈ $676.50K |
-15.87% |
| 2019-06-30 | AU$1.14 Million ≈ $804.07K |
+32.59% |
| 2018-06-30 | AU$857.04K ≈ $606.41K |
-- |
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic ra… Read more